Market Overview

UPDATE: Jefferies Downgrades GlaxoSmithKline to Hold on Margin Expansion Visibility

Share:
Related GSK
5 NYSE Healthcare Stocks With The Highest ROE
Chardan: Sell Axovant Sciences, RVT-101 Market Pricing Is 'Highly Irrational'
Can Hepatitis B Be A Blockbuster Bug? (Investor's Business Daily)

Jefferies cut its rating on GlaxoSmithKline (NYSE: GSK) from Buy to Hold on reduced visibility to the company's margin expansion.

Jefferies commented, "Whilst we still see double digit CORE EPS growth for GlaxoSmithKline from 2013E-17E, visibility on margin expansion has been obscured by over-exposure to price pressure and transfer pricing in Europe. The shares have recovered well from their lows since the Q2'12 results and we take this opportunity to cut our rating to Hold from Buy given the limited upside."

GlaxoSmithKline closed at $46.84 on Friday.

Latest Ratings for GSK

DateFirmActionFromTo
Jun 2015Morgan StanleyDowngradesOverweightEqualweight
Jan 2015New Street ResearchDowngrades
Jul 2014MainfirstDowngradesUnderperform

View More Analyst Ratings for GSK
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (GSK)

Around the Web, We're Loving...

Get Benzinga's Newsletters